659 related articles for article (PubMed ID: 25510952)
1. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
Siegmund HU; Burghaus R; Kubitza D; Coboeken K
Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
[TBL] [Abstract][Full Text] [Related]
2. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
Moore KT; Byra W; Vaidyanathan S; Natarajan J; Ariyawansa J; Salih H; Turner KC
Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601
[TBL] [Abstract][Full Text] [Related]
3. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
[TBL] [Abstract][Full Text] [Related]
4. The rivaroxaban-adjusted normalized ratio: use of the prothrombin time to monitor the therapeutic effect of rivaroxaban.
Kim B; Jang S; Lee YJ; Park N; Cho YU; Park CJ
Br J Biomed Sci; 2019 Jul; 76(3):122-128. PubMed ID: 30967043
[No Abstract] [Full Text] [Related]
5. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
[TBL] [Abstract][Full Text] [Related]
6. Oral anticoagulant initiation: rationale for the use of warfarin dosing nomograms.
Crowther MA
Semin Vasc Med; 2003 Aug; 3(3):255-60. PubMed ID: 15199458
[TBL] [Abstract][Full Text] [Related]
7. Is Rivaroxaban a Safe Choice for Apical Thrombus in Atrial Fibrillation Patients? A Case Report.
Aydin F; Turgay Yildirim O; Huseyinoglu Aydin A; Dagtekin E; Aksit E
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e203-e205. PubMed ID: 29735275
[TBL] [Abstract][Full Text] [Related]
8. Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population.
Kitagawa F; Ishii J; Hiramitsu S; Takahashi H; Okuyama R; Kawai H; Muramatsu T; Harada M; Motoyama S; Naruse H; Matsui S; Sarai M; Hayashi M; Watanabe E; Izawa H; Ozaki Y
Heart Vessels; 2017 May; 32(5):609-617. PubMed ID: 27796530
[TBL] [Abstract][Full Text] [Related]
9. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
[TBL] [Abstract][Full Text] [Related]
10. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
[TBL] [Abstract][Full Text] [Related]
11. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.
Kubitza D; Becka M; Mück W; Krätzschmar J
Br J Clin Pharmacol; 2014 Aug; 78(2):353-63. PubMed ID: 24528331
[TBL] [Abstract][Full Text] [Related]
13. Which oral anticoagulant for atrial fibrillation.
Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
[No Abstract] [Full Text] [Related]
14. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.
Douxfils J; Chatelain B; Hjemdahl P; Devalet B; Sennesael AL; Wallemacq P; Rönquist-Nii Y; Pohanka A; Dogné JM; Mullier F
Thromb Res; 2015 May; 135(5):852-60. PubMed ID: 25743887
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
[TBL] [Abstract][Full Text] [Related]
17. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.
Harenberg J; Marx S; Krämer R; Giese C; Weiss C
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):637-41. PubMed ID: 21986465
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of anti-Xa monitoring and differential sensitivity of prothrombin time assays: an illustrated case report.
Than H; Loh JB; Sum CL; Ng HJ
J Clin Pathol; 2015 Apr; 68(4):318-9. PubMed ID: 25688138
[No Abstract] [Full Text] [Related]
20. Extended International Normalized Ratio testing intervals for warfarin-treated patients.
Barnes GD; Kong X; Cole D; Haymart B; Kline-Rogers E; Almany S; Dahu M; Ekola M; Kaatz S; Kozlowski J; Froehlich JB
J Thromb Haemost; 2018 Jul; 16(7):1307-1312. PubMed ID: 29763979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]